Date: January 30 2019
Presenter(s): Maciej J. Zamek-Gliszczynski, Ph.D.
Summary of the Presentation:
This presentation will summarize the state-of-the-art in transporters in drug development based on four recent ITC3 whitepapers (Clin Pharmacol Ther 104, October 2018). Practical overview of emerging transporters of clinical relevance will be provided (e.g., OCT1, OATP2B1, etc.). Best practice in design of clinical DDI studies will be illustrated with recent advances in the study of OCT1, P-gp, and BCRP. Considerations for optimal selection of clinical probe drugs, including future potential utility of transporter biomarkers, also will be discussed.
Maciej J. Zamek-Gliszczynski, Ph.D.
GSK Senior Fellow and Director, Quantitative Drug Disposition, GlaxoSmithKline
Maciej Zamek-Gliszczynski has 15 years of industry (Eli Lilly and GSK) experience in supporting DMPK and PK/PD aspects of oncology, endocrine/metabolic, and infectious disease programs at all stages between discovery, clinical development, and post-marketing. He is currently leading Quantitative Drug Disposition, a world-wide group responsible for mechanistic understanding of PK and DDIs in the GSK portfolio. Dr. Zamek-Gliszczynski’s research is focused on clinical PK/PD and DDI implications of drug and metabolite transport. He is the author of >100 manuscripts and presentations on this subject (>4,000 cites, h-index = 31). He serves on the editorial boards of Pharmaceutical Research and Drug Metabolism and Disposition. Dr. Zamek-Gliszczynski is a member of the International Transport Consortium (ITC) steering committee, was past chair of AAPS PPDM section and AAPS Drug Transport FG, as well as GSK management representative on IQ DMLG. He has been active in organizing DMPK/clinical pharmacology meetings, including several AAPS and ITC/ASCPT Workshops. Dr. Zamek-Gliszczynski lectures in graduate-level PK/PD courses and serves as external committee advisor (including as adjunct prof at UNC). He enjoys developing scientists and has an established mentorship record at the associate scientist, junior and peer Ph.D., as well as graduate student and post-doc levels.